Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cuprina Holdings (Cayman)CUPR +0.76%10 Equity-to-Asset is 0.59 as of Dec. 2025. GuruFocus rates CUPR with a GF Score™ of 10/100. The stock has 6 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Cuprina Holdings (Cayman) ranks worse than 56.98% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cuprina Holdings (Cayman) Equity-to-Asset Related Terms
Cuprina Holdings (Cayman) Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CUPR vs BNGO, UEEC, FEMY: Equity-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, Cuprina Holdings (Cayman)'s Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cuprina Holdings (Cayman) Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cuprina Holdings (Cayman)'s Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cuprina Holdings (Cayman)'s Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cuprina Holdings (Cayman)'s Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cuprina Holdings (Cayman) (CUPR) has a Equity-to-Asset of 0.59 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cuprina Holdings (Cayman) and its competitors. According to the industry distribution chart, Cuprina Holdings (Cayman) ranks #486 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 57%.
Is Cuprina Holdings (Cayman)'s Equity-to-Asset too high?
Cuprina Holdings (Cayman)'s current Equity-to-Asset is 0.59. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Cuprina Holdings (Cayman)'s value of 0.59 is 9.2% below this industry median. Based on the distribution chart, Cuprina Holdings (Cayman) ranks #486 out of 853 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Cuprina Holdings (Cayman) has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Cuprina Holdings (Cayman)'s Equity-to-Asset compare to BNGO and UEEC?
According to the Medical Devices & Instruments industry distribution chart, Cuprina Holdings (Cayman) ranks #486 out of 853 companies for Equity-to-Asset. This places Cuprina Holdings (Cayman) in the lower half of its industry. The industry median Equity-to-Asset is 0.65. Cuprina Holdings (Cayman)'s value of 0.59 is 9.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cuprina Holdings (Cayman)'s current Equity-to-Asset of 0.59 is 9.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cuprina Holdings (Cayman) and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cuprina Holdings (Cayman)'s current Equity-to-Asset is 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cuprina Holdings (Cayman) stock overvalued right now?
Cuprina Holdings (Cayman) (CUPR) has a current Equity-to-Asset of 0.59. The current Equity-to-Asset is 0.59 and 9.2% below the Medical Devices & Instruments industry median of 0.65. Cuprina Holdings (Cayman)'s overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cuprina Holdings (Cayman) (CUPR), the current Equity-to-Asset is 0.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.
10GF Score
Get the complete analysis for CUPR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUPR has been successfully added to your 
